<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778583</url>
  </required_header>
  <id_info>
    <org_study_id>024/NITRO-100/03</org_study_id>
    <nct_id>NCT00778583</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions</brief_title>
  <official_title>An Open Label, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Nitrofurantoin Formulations Comparing Nitrofurantoin 100 mg Capsules of Ranbaxy Laboratories With Macrobid 100 mg Capsules in Healthy, Adult, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, randomised, two-treatment, four-period, two-sequence, single-dose, crossover,
      fully replicated bioavailability study on Nitrofurantoin formulations comparing
      Nitrofurantoin 100 mg capsules of Ranbaxy Laboratories with Macrobid 100 mg capsules in
      healthy, adult, human subjects under fed conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomized, single-dose, four period fully replicate crossover,
      relative bioavailability study performed on 40 healthy adult male and. A total of 35
      completed the clinical phase of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitrofurantoin 100 mg capsules of Ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Macrobid 100 mg capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin 100 mg capsules</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be in the age range of 18-45 years.

          -  Be neither overweight nor underweight for his/her height as per the Life insurance
             Corporation of India height/weight chart for non-medical cases.

          -  Have voluntarily given written informed consent to participate in this study.

          -  Be of normal health as determined by medical history and physical examination of the
             subjects performed within 14 days prior to the commencement of the study.

          -  If female and:

          -  Of childbearing potential, is practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence; or

          -  Is postmenopausal for at least I year; or

          -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy).

        Exclusion Criteria:

          -  History of allergy to nitrofurantoin and/or other related drugs.

          -  Any evidence of organ dysfunction or any clinically significant deviation from the
             normal, in physical or clinical determinations.

          -  Evidence of haemolysis (for glucose-6-phosphotase) deficiency.

          -  Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses or syphilis
             infection.

          -  Female volunteers demonstrating a positive pregnancy test.

          -  Female volunteers who are currently breastfeeding.

          -  Presence of values which are significantly different from normal reference ranges (as
             defined in Appendix 5) and/or judged clinically significant for haemoglobin, total
             white blood cells count, differential WBC count or platelet count.

          -  Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids)

          -  Presence of values which are significantly different from normal reference ranges (as
             defined in Appendix 5) and/or judged clinically significant for serum creatinine,
             blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine
             aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or
             serum cholesterol.

          -  Clinically abnormal chemical and microscopic examination of udne defined as presence
             of RI3C, WBC (&gt;4/HPF), epithelial cells (&gt;4/HPF), glucose (positive) or protein
             (positive).

          -  Clinically abnormal ECG or Chest X-ray. History of serious gastrointestinal, hepatic,
             renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes,
             glaucoma or gout.

          -  History of any psychiatric illness which may impair the ability to provide written
             informed consent.

          -  Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining
             from smoking for the duration of each study period.

          -  History of drug dependence or excessive alcohol intake on a habitual basis of more
             than 2 units of alcoholic beverages per day (1 unify.equivalent to half pint of beer
             or ! glass of wine or 1 measure of spirit)or have difficulty in abstaining for the
             duration of each study period.

          -  Use of any enzyme modi~ing drugs within 30 days prior to Day 1 of this study.

          -  Participation in any clinical trial within 12 weeks preceding Day ! of this study.

          -  A haemoglobin concentration of less than 7 % of lower limit of reference range e.g. 13
             gm % for reference range of 14-18 gm at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ranbaxy Research Laboratories</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Laboratories</organization>
  </responsible_party>
  <keyword>Bioequivalence Nitrofurantoin capsules</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrofurantoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

